1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Adocia S.A.

Adocia S.A.

ADOCY
Adocia S.A.US flagOther OTC
11.80
USD
- -
- -
170.44MMarket Cap
Adocia S.A.
ADOCY
(Other OTC)

Recent

price

11.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
0.03
0.35
0.67
0.9
0.11
5.52
3.28
2.84
6.85
0.31
0.12
0.2
1.43
0.15
0.63
Revenue per Share
-1.17
-1.45
-1
-0.69
-3.33
1.88
-1.15
-1.25
1.1
-2.68
-3.34
-3.22
-0.86
-1.5
-0.63
Basic EPS, GAAP
-1.26
-1.44
0.03
-1.81
4.85
-1.12
-3.1
-3.53
0.8
-1.68
-3.16
-2.78
-1.89
-0.36
-1.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.06
-1.35
-0.9
-0.59
-3.23
1.98
-1.05
-1.15
1.2
-2.58
-3.24
-3.12
-0.75
-1.4
-0.52
Book Value per Share
2.64
0.97
3.85
3.08
0.4
7.03
6.25
5.36
6.61
4.03
0.9
-1.96
-1.62
-0.49
-0.21
Tangible Book Value per Share
4
4
6
6
6
7
7
7
7
7
7
7
8
14
15
Basic Weighted Avg Shares
- -
2
4
6
1
37
22
19
47
2
1
1
11
2
9
Sales/Revenue/Turnover
-4,178.38
-391.68
-151.9
-76.95
-2,437.5
27.35
-35.58
-42.01
20.49
-1,027.53
-2,514.74
-1,341.07
-14.82
-662.51
-79.41
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
1
- -
- -
Depreciation Expense
-5
-6
-6
-4
-21
13
-8
-9
8
-19
-23
-23
-7
-21
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
35.24
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-4,262.16
-416.12
-150.03
-76.81
-2,942.47
33.98
-35.09
-43.92
16.07
-868.08
-2,773.37
-1,575.76
-60.29
-984.28
-100
Profit Margin (%)
12
6
24
20
31
66
42
36
46
41
26
-2
1
- -
2
Working Capital
2
2
2
2
1
1
6
6
5
19
25
18
18
11
9
LT Debt
11
4
23
19
3
47
43
37
46
28
6
-14
-13
-7
-3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
12.82
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
101.89
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
123.73%
-100.73%
-55.32%
Free Cash Flow
-16.28%
39.81%
210.24%
Net Income, GAAP
-74.45%
20.79%
-55.95%
Sales/Revenue/Turnover
609.81%
191.2%
333.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
11
2023
- -
- -
- -
- -
2
2024
- -
- -
- -
- -
9

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.86
2023
- -
- -
- -
- -
-1.5
2024
- -
- -
- -
- -
-0.63

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
enGene Holdings Inc. Warrants (ENGNW)
Valneva SE (0OB3.L)
Oncolys BioPharma Inc. (4588.T)
Redwood Pharma AB (REDW.ST)
Protagonist Therapeutics, Inc. (PTGX)
Sangamo Therapeutics, Inc. (0R1D.L)
Business
Adocia SA (ADOCY) is a French clinical-stage biotechnology company that develops innovative formulations of approved therapeutic proteins and peptides, as well as cell therapy approaches, primarily for the treatment of diabetes and obesity. Founded in 2005 and headquartered in Lyon, France, the company operates through four proprietary technology platforms—BioChaperone®, AdoShell®, AdOral®, and AdoGel®—targeting type 1 and type 2 diabetes, obesity, and related metabolic diseases; its diversified pipeline includes BioChaperone Lispro, an ultra-rapid prandial insulin formulation licensed to Tonghua Dongbao Pharmaceutical Co., Ltd. for China and select Asian territories, which completed Phase 3 trials with positive topline results in type 1 and type 2 diabetes patients in 2025; BioChaperone Combo, a fixed combination of insulin glargine and lispro for improved glycemic control in type 2 diabetes; M1Pram and BioChaperone LisPram, co-formulations of insulin analogs with pramlintide (amylin analog) under exclusive option rights with Sanofi for obesity management in insulin-dependent patients; AdoShell Islets, an immunoprotective hydrogel implant for retrievable islet cell therapy in type 1 diabetes; AdOral Sema, an oral semaglutide GLP-1 receptor agonist; AdoGel Sema, a long-acting injectable hydrogel for semaglutide delivery; and BioChaperone GLP-1 Amylin, a combination for metabolic control. Adocia focuses on licensing its products and platforms to pharmaceutical partners after human proof-of-concept, with operations centered in Europe and strategic alliances extending to Asia and potential global expansion. Recent developments include a €10 million fundraising in December 2025 from CVI Investments, Inc., extending cash runway into early 2027 and supporting industrialization of BioChaperone technology and the new AdoXLong long-acting peptide platform for which a patent was filed in November 2025; a €9.7 million private placement in February 2025; positive Phase 3 data announcements with Tonghua Dongbao in mid-2025 for BioChaperone Lispro; ongoing partnership discussions with Sanofi for M1Pram; and presentations on AdoShell scalability at scientific conferences in 2025.